Eli Lilly and Company has announced a new commitment to improve the long-term health of communities in Brazil, China, India, Kenya, Mexico, Russia, South Africa, and the United States by 2030.

The cornerstone of that goal, known as Lilly 30x30, is the Lilly Global Health Partnership, a five-year, $90 million initiative to improve access to treatment for thirty million people to diabetes, tuberculosis, and cancer. With half the funds coming from the Eli Lilly and Company Foundation and the other half from company funds, Lilly will work to advance its existing global health work in limited-resource communities while identifying new opportunities for partnership. Consistent with the company's evidence-based approach, the initiative will research new models of care, report findings, and advocate to scale the most effective solutions to help more people.

The new funding includes a new $15 million commitment to the Infectious Disease Research Institute, extending an eight-year collaboration to accelerate early-stage drug discovery and preclinical development for potential TB medicines.

"Lilly has a strong, hundred-and-forty-year history of improving global health that goes beyond monetary and product donations," said Lilly senior vice president David A. Ricks, who will assume the role of Lilly president and CEO on January 1. "As a research-based company, we bring deep scientific and technical expertise to develop better solutions for people around the world. The Lilly Global Health Partnership will enable us to expand our reach in significant and meaningful ways."